ABSTRACT

Repaglinide is Chemically benzoic acid derivatives. It belongs to the class of antihyperglycemic medications. Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetic mellitus (NIDDM). It is a member of the meglitinide class of short-acting insulin secretagogues, which work by binding to ? cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. Voglibose is an ?-glucosidase inhibitor and it is chemically cyclohexane-1,2,3,4-tetrol) derivatives. It is used to lower postprandial blood glucose levels in people with diabetes mellitus. The fixed-dose combination of repaglinide and voglibose is an effective pharmacologic method for controlling both fasting (FHG) and after- meal hyperglycaemia (PPHG) with adequate tolerance and safety. The dosage ratio for the fixed-dose combination of repaglinide and voglibose is 0.5:0.2 mg. The present work highlights the analytical techniques that had been developed for the estimation of repaglinide and voglibose, either alone or in combination with other drugs. We have reviewed various analytical methods, such as HPLC-UV, Stability indicating RP-HPLC, TLC,Spectrophotometric (UV-Vis), and other methods that have been developed for the combination of Repaglinide and Voglibose. Keywords: Repaglinide, Voglibose, Analytical techniques, Antidiabetic, Stability indicating RP- HPLC, UV-visible Spectrophotometer, HPLC, TLC Method
Publication date: 01/11/2024

https://ijbpas.com/pdf/2024/November/MS_IJBPAS_2024_8359.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.11.8359